|
⚲
|
| Keyboard |
| Flagship Pioneering LLC
✚
|
|
|---|---|
| CRD # | 161864 |
| SEC # | 802-75749 |
| CIK # | 0001400240 |
| AUM | |
| Employees | |
| Phone | 617-868-1888 |
| Address | 55 Cambridge Parkway Cambridge, MA 02142-1234 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] |
| Total AUM ($) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Moderna Inc | 0.2 | ||
| SANA Biotechnology Inc | 0.1 | ||
| Foghorn Therapeutics Inc | 0.1 | ||
| Seres Therapeutics Inc | 0.0 | ||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Flagship Labs VIII LLC | 2025-03-31 | 175.4 M | |
| VC | FPA II LP | 2025-03-31 | 279.9 M | |
| VC | FPS LP | 2025-03-31 | 25.0 M | |
| VC | FSP-DB Fund LP | 2025-03-31 | 145.4 M | |
| VC | ET Fund | 2024-03-29 | 279.2 M | |
| VC | Flagship Pioneering Fund VIII LP | [2024-03-29] | 2,590.6 M | 2,454.4 M |
| Offered $2,590,563,688 · Filed 2024-11-29 (D/A) · Exemption 506(c), 3(c), 3(c)(7) · Minimum $200,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | FPN III LP | 2023-03-30 | 346.4 M | |
| VC | FPA LP | 2022-03-28 | 264.4 M | |
| VC | FPN II LP | 2022-03-28 | 261.1 M | |
| VC | Flagship Labs VII LLC | 2021-03-31 | 610.2 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| Limited Partners | 2011 - 2026 |
|---|---|
| State of Michigan Retirement System |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Noubar Afeyan PhD | Executive Officer | 11 | 2 | |
| Flagship Ventures Opportunities Fund I General Partner LLC | Executive Officer | 1 | 1 | |
| General Partner LLC Flagship Ventures Fund IV | Executive Officer | 1 | 1 | |
| Flagship Pioneering Fund VIII General Partner LLC | Executive Officer | 1 | 1 | |
| General Partner LLC Flagship Ventures Fund V | Executive Officer | 1 | 1 | |
| Flagship Pioneering Fund VI General Partner LLC | Executive Officer | 1 | 1 | |
| Flagship Pioneering Special Opportunities Fund II General Partner LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001400240] | |
| 3 | [0001400240] | |
| 4 | [0001400240] | |
| SC 13G | [0001400240] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Flagship Pioneering LLC | Generate Biomedicines Inc | [2026-05-15] |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Generate Biomedicines Inc GENB
Common Stock
|
2026-03-02 | Conversion | 13,702,224 | ||
|
Generate Biomedicines Inc GENB
Common Stock
|
2026-03-02 | Buy | 1,562,500 | $16.00 | 25,000,000 |
|
Generate Biomedicines Inc GENB
Common Stock
|
2026-03-02 | Conversion | 2,777,752 | ||
|
Generate Biomedicines Inc GENB
Common Stock
|
2026-03-02 | Conversion | 2,777,752 | ||
|
Generate Biomedicines Inc GENB
Common Stock
|
2026-03-02 | Buy | 1,562,500 | $16.00 | 25,000,000 |
|
Generate Biomedicines Inc GENB
Common Stock
|
2026-03-02 | Buy | 1,562,500 | $16.00 | 25,000,000 |
|
Generate Biomedicines Inc GENB
Series C Preferred Stock · derivative
|
2026-03-02 | Conversion | 1,265,822 | $0.00 | |
|
Generate Biomedicines Inc GENB
Series C Preferred Stock · derivative
|
2026-03-02 | Conversion | 2,109,704 | $0.00 | |
|
Generate Biomedicines Inc GENB
Series B Preferred Stock · derivative
|
2026-03-02 | Conversion | 843,881 | $0.00 | |
|
Generate Biomedicines Inc GENB
Series B Preferred Stock · derivative
|
2026-03-02 | Conversion | 2,109,704 | $0.00 | |
|
Generate Biomedicines Inc GENB
Common Stock
|
2026-03-02 | Conversion | 12,723,940 | ||
|
Generate Biomedicines Inc GENB
Series A Preferred Stock · derivative
|
2026-03-02 | Conversion | 18,483,785 | $0.00 | |
|
Generate Biomedicines Inc GENB
Series A Preferred Stock · derivative
|
2026-03-02 | Conversion | 17,016,215 | $0.00 | |
|
Generate Biomedicines Inc GENB
Common Stock
|
2026-03-02 | Conversion | 987,491 | ||
|
Generate Biomedicines Inc GENB
Series A Preferred Stock · derivative
|
2026-03-02 | Conversion | 1,500,000 | $0.00 | |
|
Generate Biomedicines Inc GENB
Series B Preferred Stock · derivative
|
2026-03-02 | Conversion | 2,953,586 | $0.00 | |
|
Generate Biomedicines Inc GENB
Series B Preferred Stock · derivative
|
2026-03-02 | Conversion | 1,265,822 | $0.00 | |
|
Generate Biomedicines Inc GENB
Series C Preferred Stock · derivative
|
2026-03-02 | Conversion | 2,531,644 | $0.00 | |
|
Generate Biomedicines Inc GENB
Stock Option (Right to Buy) · derivative
|
2026-02-26 | Grant | 29,561 | $0.00 | |
|
Foghorn Therapeutics Inc FHTX
Series 1 Warrants to purchase Common Stock · derivative
|
2026-01-13 | Grant | 1,117,734 | ||
| showing 20 of 200 most recent transactions | |||||